AVALO THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
AVALO THERAPEUTICS, INC. (AVTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-23
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-23 |
| 2024-12-31 | 0.00% 10-K · filed 2025-03-20 |
| 2023-12-31 | 0.00% 10-K · filed 2024-03-29 |
| 2022-12-31 | 0.00% 10-K · filed 2023-03-29 |
| 2021-12-31 | 0.00% 10-K · filed 2022-03-02 |
| 2020-12-31 | 0.00% 10-K · filed 2021-03-08 |
| 2019-12-31 | 0.00% 10-K · filed 2020-03-11 |
| 2018-12-31 | 0.00% 10-K · filed 2019-03-18 |
| 2017-12-31 | 0.00% 10-K · filed 2018-04-02 |
| 2016-12-31 | 0.00% 10-K · filed 2017-03-14 |
| 2015-12-31 | 0.00% 10-K · filed 2017-03-14 |
| 2014-12-31 | 0.00% 10-K · filed 2017-03-14 |
| 2013-12-31 | 0.00% 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |